Involvement of metalloproteinases 2/9 in epidermal growth factor receptor transactivation in pressure-induced myogenic tone in mouse mesenteric resistance arteries

Circulation

Volumn 110, Issue 23, 2004, Pages 3587-3593

  Lucchesi, Pamela A ^a   Sabri, Abdelkarim ^b   Belmadani, Souad ^b   Matrougui, Khalid ^a,c  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c Department of Pharmacology ^*  (United States)

Author keywords

Angiotensin pressure; Growth substances; Metalloproteinases; Microcirculation

Indexed keywords

4 (3 BROMOANILINO) 6,7 DIMETHOXYQUINAZOLINE; 4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; ANGIOTENSIN; EPIDERMAL GROWTH FACTOR RECEPTOR; GELATINASE A; GELATINASE B; HEPARIN; HEPARIN BINDING EPIDERMAL GROWTH FACTOR; NEUTRALIZING ANTIBODY; POTASSIUM CHLORIDE;

ARTERIOGRAPHY; ARTERY RESISTANCE; ARTICLE; CELL MEMBRANE; CONTROLLED STUDY; ENZYME ACTIVITY; MEMBRANE BINDING; MESENTERIC ARTERY; MOUSE; MUSCLE CONTRACTION; MUSCLE EXCITATION; NONHUMAN; PRESSURE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; SMOOTH MUSCLE TONE; TRANSACTIVATION; ZYMOGRAPHY;

ANGIOTENSIN II; ANIMALS; EPIDERMAL GROWTH FACTOR; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MESENTERIC ARTERIES; MICE; MICE, INBRED C57BL; MUSCLE CONTRACTION; MUSCLE TONUS; MUSCLE, SMOOTH, VASCULAR; PHOSPHORYLATION; POTASSIUM CHLORIDE; PRESSURE; RECEPTOR, EPIDERMAL GROWTH FACTOR; TRANS-ACTIVATION (GENETICS); VASCULAR RESISTANCE;

EID: 10044256495     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000148780.36121.47     Document Type: Article

References (33)

1. Davis MJ, Hill MA. Signaling mechanisms underlying the vascular myogenic response. Physiol Rev. 1999;79:387-423.
2. Drexler H, Hayoz D, Munzel T, Hornig B, Just H, Brunner HR, Zelis R. Endothelial function in chronic congestive heart failure. Am J Cardiol. 1992;69:1596-1601.
3. Matrougui K, Maclouf J, Levy BI, Henrion D. Impaired nitric oxide- and prostaglandin-mediated responses to flow in resistance arteries of hypertensive rats. Hypertension. 1997;30:942-947.
4. Matrougui K, Eskildsen-Helmond YE, Fiebeler A, Henrion D, Levy BI, Tedgui A, Mulvany MJ. Angiotensin II stimulates extracellular signal - regulated kinase activity in intact pressurized rat mesenteric resistance arteries. Hypertension. 2000;36:617-621.
5. Matrougui K, Tanko LB, Loufrani L, Gomy D, Levy BI, Tedgui A, Henrion D. Involvement of Rho-kinase and the actin filament network in angiotensin II - induced contraction and extracellular signal - regulated kinase activity in intact rat mesenteric resistance arteries. Arterioscler Thromb Vasc Biol. 2001;21:1288-1293.
6. VanBavel E, van der Meulen ET, Spaan JA. Role of Rho-associated protein kinase in tone and calcium sensitivity of cannulated rat mesenteric small arteries. Exp Physiol. 2001;86:585-592.
7. Wesselman JP, Spaan JA, van der Meulen ET, VanBavel E. Role of protein kinase C in myogenic calcium-contraction coupling of rat cannulated mesenteric small arteries. Clin Exp Pharmacol Physiol. 2001;28:848-855.
8. Bakker EN, Balt JC, Pfaffendorf M, Spaan JA, VanBavel E. Vasomotor effects of arg-gly-asp (RGD) peptides are limited and not related to endothelium-derived hyperpolarizing factor - mediated relaxation in rat mesenteric arteries. Clin Exp Pharmacol Physiol. 2001;28:873-876.
9. Hu Y, Bock G, Wick G, Xu Q. Activation of PDGF receptor alpha in vascular smooth muscle cells by mechanical stress. FASEB J. 1998;12:1135-1142.
10. 2 receptors by endogenous angiotensin II is involved in flow-induced dilation in rat resistance arteries. Hypertension. 1999;34:659-665.
11. Weber DS, Frisbee JC, Lombard JH. Selective potentiation of angiotensin-induced constriction of skeletal muscle resistance arteries by chronic elevations in dietary salt intake. Microvasc Res. 1999;57:310-319.
12. Henrion D, Amant C, Benessiano J, Philip I, Plantefeve G, Chatel D, Hwas U, Desmont JM, Durand G, Amouyel P, Levy BI. Angiotensin II type 1 receptor gene polymorphism is associated with an increased vascular reactivity in the human mammary artery in vitro. J Vasc Res. 1998;35:356-362.
13. Dowell FJ, Henrion D, Benessiano J, Poitevin P, Levy B. Chronic infusion of low-dose angiotensin II potentiates the adrenergic response in vivo. J Hypertens. 1996;14:177-182.
14. Rocic P, Govindarajan G, Sabri A, Lucchesi PA. A role for PYK2 in regulation of ERK1/2 MAP kinases and PI 3-kinase by Ang II in vascular smooth muscle. Am J Physiol. 2001;280:C90-C99.
15. Rocic P, Griffin TM, McRae CN, Lucchesi PA. Altered PYK2 phosphorylation by Ang II in hypertensive vascular smooth muscle. Am J Physiol. 2002;282:H457-H465.
16. Rocic P, Lucchesi PA. Down-regulation by antisense oligonucleotides establishes a role for the proline-rich tyrosine kinase PYK2 in angiotensin II - induced signaling in vascular smooth muscle. J Biol Chem. 2001;276:21902-21906.
17. Kalmes A, Daum G, Clowes AW. EGFR transactivation in the regulation of SMC function. Ann N Y Acad Sci. 2001;947:42-54; discussion 54-55.
18. Hao L, Du M, Lopez-Campistrous A, Fernandez-Patron C. Agonist-induced activation of matrix metalloproteinase-7 promotes vasoconstriction through the epidermal growth factor-receptor pathway. Circ Res. 2004;94:68-76.
19. Heo JH, Lucero J, Abumiya T, Koziol JA, Copeland BR, del Zoppo GJ. Matrix metalloproteinases increase very early during experimental focal cerebral ischemia. J Cereb Blood Flow Metab. 1999;19:624-633.
20. Asakura M, Kitakaze M. The role of HB-EGF in angiotensin II - signaling [in Japanese]. Nippon Rinsho. 2002;60:1916-1921.
21. Asakura M, Kitakaze M, Takashima S, Liao Y, Ishikura F, Yoshinaka T, Ohmoto H, Node K, Yoshino K, Ishiguro H, Asanuma H, Sanada S, Matsumura Y, Takeda H, Beppu S, Tada M, Hori M, Higashiyama S. Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: metalloproteinase inhibitors as a new therapy. Nat Med. 2002;8:35-40.
22. Black RA, White JM. ADAMs: focus on the protease domain. Curr Opin Cell Biol. 1998;10:654-659.
23. Chester NC, Ku DN, Galis ZS. Transmural pressure induces matrix-degrading activity in porcine arteries ex vivo. Am J Physiol. 1999;277:H2002-H2009.
24. Osol G, Laher I, Cipolla M. Protein kinase C modulates basal myogenic tone in resistance arteries from the cerebral circulation. Circ Res. 1991;68:359-367.
25. Hill MA, Falcone JC, Meininger GA. Evidence for protein kinase C involvement in arteriolar myogenic reactivity. Am J Physiol. 1990;259:H1586-H1594.
26. Massett MP, Ungvari Z, Csiszar A, Kaley G, Koller A. Different roles of PKC and MAP kinases in arteriolar constrictions to pressure and agonists. Am J Physiol. 2002;283:H2282-H2287.
27. Spurrell BE, Murphy TV, Hill MA. Intraluminal pressure stimulates MAPK phosphorylation in arterioles: temporal dissociation from myogenic contractile response. Am J Physiol. 2003;285:H1764-H1773.
28. Eguchi S, Dempsey PJ, Frank GD, Motley ED, Inagami T. Activation of MAPKs by angiotensin II in vascular smooth muscle cells: metalloprotease-dependent EGF receptor activation is required for activation of ERK and p38 MAPK but not for JNK. J Biol Chem. 2001;276:7957-7962.
29. Bokemeyer D, Schmitz U, Kramer HJ. Angiotensin II - induced growth of vascular smooth muscle cells requires an Src-dependent activation of the epidermal growth factor receptor. Kidney Int. 2000;58:549-558.
30. Nose A, Mori Y, Uchiyama-Tanaka Y, Kishimoto N, Maruyama K, Matsubara H, Iwasaka T. Regulation of glucose transporter (GLUT1) gene expression by angiotensin II in mesangial cells: involvement of HB-EGF and EGF receptor transactivation. Hypertens Res. 2003;26:67-73.
31. Tanko LB, Matrougui K. Can we apply results from large to small arteries? Circ Res. 2002;90:e68.
32. 2+ influx in cerebral arteries. Am J Physiol. 2002;282:H1410-H1420.
33. Hill MA, Meininger GA. Calcium entry and myogenic phenomena in skeletal muscle arterioles. Am J Physiol. 1994;267:H1085-H1092.